Linezolid Crescent Pharma (Linezolid)

Linezolid blocks bacterial protein synthesis by binding to the 50S ribosomal subunit. This prevents formation of the initiation complex needed for translation, halting production of essential proteins and resulting in a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage regimen for linezolid is determined by the prescribing clinician based on the specific infection, patient age, weight, renal and hepatic function, and local guidelines. Only a qualified healthcare professional should set the dose and duration of therapy.

The safety of linezolid in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linezolid offers oral bioavailability comparable to intravenous administration, making it convenient for step‑down therapy. Unlike many beta‑lactams, it remains active against MRSA and VRE. However, it lacks activity against Gram‑negative organisms and may have a higher risk of hematologic toxicity compared with some alternatives.

Store the oral tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed to maintain product stability.

Linezolid Crescent Pharma is supplied as oral tablets that are taken by mouth with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events include thrombocytopenia, peripheral neuropathy, serotonin syndrome when combined with serotonergic drugs, myelosuppression, lactic acidosis, and optic neuritis. Patients should be monitored regularly for blood‑count changes and neurological symptoms, and any concerning signs should prompt immediate medical evaluation.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in individuals taking monoamine oxidase inhibitors or other serotonergic agents due to the risk of serotonin syndrome, unless the benefits clearly outweigh the risks.